Regeneron Pharmaceuticals announced topline success in its phase III Optima trial for garetosmab, a monoclonal antibody targeting fibrodysplasia ossificans progressiva (FOP), a rare skeletal disorder characterized by aberrant bone growth. The trial demonstrated substantial reductions in new bone lesions, with 94% and 90% decreases at two dose levels compared to placebo. Regeneron plans to submit the data to the FDA for approval by year-end. Additionally, updated phase II data from Regeneron’s Courage trial in obesity therapy showed promising results combining semaglutide with anti-myostatin agents, advancing obesity treatment options. These pivotal clinical advances may significantly impact therapeutic approaches to rare bone diseases and metabolic disorders.